Johnson & Johnson raised its full-year outlook after reporting fiscal Q2 2026 sales of $25.31 billion, up 6.6% year over year and above the $25.05 billion consensus, with adjusted earnings per share of $2.90 beating estimates of $2.85. The company lifted its full-year reported sales guidance midpoint to $101.1 billion from $100.8 billion and increased its adjusted earnings-per-share forecast midpoint by $0.13 to $11.68. Medtronic, meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade, reporting fourth-quarter revenue of $9.8 billion, up 9.9% as reported, and full-year revenue of $36.4 billion, up 8.4% as reported. Johnson & Johnson's Innovative Medicine segment grew 7.8% to $16.38 billion, driven by oncology, immunology, and neuroscience, while Medtronic's cardiac ablation solutions revenue rose 78% globally. The analysis concludes Johnson & Johnson offers more diversified and proven growth, while Medtronic presents a higher-upside turnaround with greater execution risk.
